Core Insights - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair growth and anti-hair loss: small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016) [1] - The combination formula of these two molecules has shown significant superiority in hair growth and anti-hair loss effects, safety, and onset speed compared to existing similar products through rigorous human trials [1] - Both molecules have successfully passed the INCI (International Nomenclature of Cosmetic Ingredients) registration in the United States, and the combination product Groland has received FDA (Food and Drug Administration) cosmetic filing, marking Jingtai's entry into the promising consumer health sector [1] - Jingtai aims to tackle major diseases through drug development while also creating consumer-grade molecular products to enhance the quality of daily life [1] - The new mission statement of Jingtai emphasizes the integration of AI into every new drug and the incorporation of AI molecules into everyone's quality of life [1] Company Developments - The AI molecular discovery platform of Jingtai is focused on developing innovative drug molecules that save lives and creating safe and effective consumer product molecules [1] - The successful validation of the dual active ingredients positions Jingtai as a leader in the consumer health market, leveraging its AI capabilities [1]
晶泰控股：晶泰AI创新研发平台成功开发生发“双子星”新分子 获得关键国际认证